Davenham

Companies: DAV   
31/07/2008

Asset-based lender Davenham, brought to AIM back in 2005 at 254p and originally recommended by Growth Company Investor at 365.5p, has suffered a dramatic recent share price fall on worries about its exposure to the under-fire UK SME sector.

This isn’t the most appealing market to be lending to given the current market malaise, and astute chief executive David Coates readily admits that recent trading has been more challenging. However, he says full year results for the year to June – due for release in September – will meet market forecasts, reflecting the strict lending risk controls built into the business over recent years as well as a recent more cautious approach to loan growth, particularly in the property division, put in place last autumn.

Coates insists the company continues to benefit from strong demand for its asset and trade finance products, as the credit crunch hit clearing banks remain more cautious in these areas.

We think Davenham should be given more credit for its track record, having grown profits by 17% to £12.1m last year. Based on forecasts in the market for June – profits of £13.3m, 37p of earnings and a 16.9p dividend – the shares look substantially oversold on a p/e of 2.7.

Considering the shares yield 17% on those numbers, there is little sense in selling if you’ve yet to do so by now. Buy/hold.

Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.

James Crux

Related Articles:
28/11/2008
28/11/2008
27/11/2008
25/11/2008
25/11/2008

People who read this article also read ...
05/08/2008
05/08/2008
01/08/2008
30/07/2008
29/07/2008

AIM£3.13m 12.00p -1.00p
Other company articles:
03/11/2008
31/07/2008
06/03/2008
11/09/2007
09/08/2007

Sponsored Listings

Manage Your Finances Money, tax and benefits : your official guide.

Recommendations

Hyder Consulting

STRONG BUY

Relax Group

HOLD

Digital Marketing

BUY/HOLD

Lo-Q

HOLD

Hardy Underwriting Bermuda

HOLD

Hiscox

ADD

Norcros

SPECULATIVE BUY

IdaTech

AVOID

Intellego Holdings

AVOID

Medilink-Global UK

SPECULATIVE BUY
AIM